Glioma is the most common primary intra-axial tumor in dogs and people carrying a poor prognosis. Our goal is to develop effective immunotherapies with minimal adverse effects. We are conducting clinical trials on dogs with glioma using tumor lysate-based vaccines after surgery to stimulate a tumor specific immune response to kill residual tumor.
展开▼
